Jump to content
  • Sign Up
×
×
  • Create New...
New feature: 1 Vote = 0.10€ for server Owner!

Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

Pelican Press

By Pelican Press,
in World News

 Share

Recommended Posts

  • Diamond Member
Pelican Press Warlord

Pelican Press 0

Posted
  • Diamond Member
Posted

This is the hidden content, please

Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. 

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.



This is the hidden content, please

#Novo #Nordisk #shares #pop #earlystage #weight #loss #drug #trial #results

This is the hidden content, please

This is the hidden content, please

0

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Unfortunately, your content contains terms that we do not allow. Please edit your content to remove the highlighted words below.
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
 Share
Go to topic listing

  • Vote for the server

    To vote for this server you must login.

    Jim Carrey Flirting GIF

  • Recently Browsing   0 members

    • No registered users viewing this page.

Important Information

Privacy Notice: We utilize cookies to optimize your browsing experience and analyze website traffic. By consenting, you acknowledge and agree to our Cookie Policy, ensuring your privacy preferences are respected.

  I accept